Astellas Unit, Pfizer Sue To Bar Roxane's Generic Tarceva

Law360, New York (April 13, 2012, 2:17 PM EDT) -- Astellas Pharma Inc. unit OSI Pharmaceuticals LLC, Pfizer Inc. and Genentech Inc. on Friday sued Roxane Laboratories Inc. in Delaware federal court over Roxane’s bid for approval to market a generic version of the cancer treatment Tarceva.

The lawsuit asserts three patents and names Boehringer Ingelheim Corp. subsidiary Roxane as the sole defendant. Genentech is a co-exclusive licensee of all three patents. OSI, which Astellas bought for $4 billion in 2010, owns two of the patents and co-owns the third with Pfizer, according to the complaint....
To view the full article, register now.